Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px
Document › Details

Fluidigm Corporation. (5/4/17). "Press Release: European Mass Cytometry Consortium Brings CyTOF Technology to Leading Universities to Advance Clinical Research". South San Francisco, CA.

Region Region United Kingdom (GB)
Organisations Organisation Fluidigm Corporation (Nasdaq: FLDM)
  Group Fluidigm (Group)
  Organisation 2 MRC Consortium for Mass Cytometry
  Group United Kingdom (GB) (govt)
Products Product Helios™ mass cytomtery system (CyTOF® platform)
  Product 2 mass cytometry
Index term Index term United Kingdom (govt)–Fluidigm: mass cytrometry, 201705 supply 7 Helios mass cytometry systems to new MRC Consortium for Mass Cytometry
Persons Person Beynon, Robert (Rob) (Univ Liverpool 201402 Prof Dept of Integrative Biology + Head Mass Spec Facilty)
  Person 2 Slupsky, Joseph (Univ Liverpoold 201705 Academic Lead of Cell Sorting + Mass Cytometry Facility)
     


Fluidigm Corporation (NASDAQ:FLDM) today announced that leading research institutions in the UK have partnered to acquire and implement seven Helios™ mass cytometry systems to empower life-changing discoveries in human health. Supported by the Clinical Research Infrastructure Initiative (CRII) of the UK Medical Research Council (MRC), the MRC Consortium for Mass Cytometry includes researchers from the universities of Liverpool, Manchester, Newcastle, Cambridge, Birmingham and Oxford and University College London.

Helios utilizes CyTOF® technology to enable deep profiling of translational and clinical research samples across a range of cell surface and intracellular markers by mass cytometry. Designed to significantly reduce signal overlap, mass cytometry empowers researchers to simultaneously interrogate cellular phenotypes, function and signaling status in higher dimension than traditional fluorescent methods. Mass cytometry is especially valuable in research studies when sample volumes are limited.

In support of the MRC Consortium for Mass Cytometry, Fluidigm sponsored the 2017 UK Mass Cytometry User Meeting, a two-day symposium held in London on March 21 and 22. This meeting brought together scientists from 19 major UK research centers to share recent research advances and best practices in mass cytometry.

"The Technology Directorate at Liverpool led the procurement and development of the MRC Consortium for Mass Cytometry in the UK," said Professor Robert Beynon, PhD, academic head of the Technology Directorate at the University of Liverpool. "By organizing the UK users meeting, Fluidigm is helping to make this vision, of pooled knowledge and shared infrastructure, a reality."

Symposium speakers included scientists from within the MRC consortium as well as mass cytometry users from other locations and technical specialists from Fluidigm. Topics included fundamentals of instrument operation and sample preparation, design of high-parameter biomarker panels, best practices for integrating mass cytometry into a core facility and cutting-edge research underway at several consortium locations.

"My favorite aspects of the meeting were being able to hear and discuss how the different groups associated with the consortium (and indeed other mass cytometry users outside the consortium) have developed and use the technology for different aspects of research, and also how they have adapted mass cytometry within their core service providers for wider use by their universities," said Joseph Slupsky, PhD, academic lead for the University of Liverpool Cell Sorting and Mass Cytometry Facility.

Dr. Slupsky's research is focused on chronic lymphocytic leukemia (CLL). "I am using mass cytometry to measure phenotypic changes, signal transduction and gene expression within distinct subpopulations of CLL cells," Dr. Slupsky said. "Mass cytometry will also be used to understand patient response to drug therapy in this disease and gain insight into the mechanisms of drug toxicity and efficacy."

"We are enthusiastic about the collective power of the MRC Consortium for Mass Cytometry to achieve new breakthroughs in an environment of shared infrastructure and best practices," said Chris Linthwaite, President and CEO of Fluidigm. "The great progress these institutions have made since the successful installation of these seven systems was evident at our recent UK user meeting."


About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Fluidigm, the Fluidigm logo, CyTOF, and Helios are trademarks or registered trademarks of Fluidigm Corporation.


Contact:

Michaeline Bunting
Senior Director, Marketing
Fluidigm Corporation
650 737 4190
michaeline.bunting@fluidigm.com

   
Record changed: 2017-05-07

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px

More documents for Fluidigm (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BCNP Consultants European Chemistry Partnering 2018 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px